

CURRICULUM VITAE DI EMIDIO SCARPELLINI

Titoli di studio:

scuola dell'obbligo:. Pagliare del Tronto, Ascoli Piceno
Settembre 1985 - Giugno 1993.

Scuola superiore: Liceo Classico " F. Stabili " , Ascoli Piceno
Settembre 1994 - Giugno 1998.

Università: facoltà di Medicina e Chirurgia,
Università Cattolica del Sacro Cuore,
Policlinico Universitario A. Gemelli, Roma
Ottobre 1998 - Luglio 2004
110/110 con lode.

Specializzazione in Medicina Interna
Ottobre 2009
Università Cattolica del Sacro Cuore,
Policlinico Universitario A. Gemelli, Roma
50/50 con lode.

Titoli ed esperienze post-laurea:

Agosto 2003 - Ottobre 2009: Specializzazione in Medicina Interna

Ricerca clinica Condotta presso il Dipartimento di Medicina Interna, sotto la direzione del Prof. A. Gasbarrini (Ottobre 2004 – Maggio 2009);

Visiting research Fellow presso " Laboratory of Gastrointestinal Motility ", Leuven, Belgio, sotto la direzione del Prof. J. Tack (Gennaio 2008 – Febbraio 2009);

Phd presso Università Cattolica del Sacro Cuore, Policlinico Universitario A. Gemelli, Roma in " Fisiopatologia del metabolismo e della nutrizione ", conseguito il 13 Marzo 2013 con la votazione di 30/30 con lode e premio del miglior dottorato di ricerca dell'anno accademico 2012-2013;

PhD in " Biomedical Sciences " Doctoral School, KULeuven con il progetto " Pharmacotherapy of gastrointestinal motility in man ", promoter Prof. Jan Tack, conseguito con il Massimo dei voti il 27 Febbraio 2014.

Posizioni lavorative:

- Ricercatore a tempo determinato in Medicina Interna (MED012) presso Università " La Sapienza " di Roma da Marzo 2012 fino a Febbraio 2015 con attività di ricerca clinica in ambito epatologico presso l'Unità di Gastroenterologia diretta dal Prof. A.F. Attili; ecografia addominale epato-biliare sotto la supervisione del Prof. A. De Santis;

- Assegnista di Ricerca presso l'Unità di Gastroenterologia degli " Ospedali Riuniti di Ancona" , diretta dal Dott. P. Mosca (da Maggio a Settembre 2015);
- Libero professionista in Medicina Interna presso "Villa Stuart" Private Rehabilitation Clinic, Roma (since Ottobre 2012 fino al 15 Dicembre 2015);
- Dirigente Medico in Medicina Interna presso l'Unità operativa di Medicina Interna, diretta dal Dott. P. Santori, Ospedale di San Benedetto del Tronto (dal 16 Dicembre 2015 fino ad ora);
- Visiting Postdoctoral Researcher presso T.A.R.G.I.D., KULeuven, Leuven, Belgio (dal 1° Aprile 2020 ad oggi);
- Responsabile Ambulatorio CUP Regionale " malattie epatiche " dal Settembre 2022 ad oggi (gestione di pazienti con epatopatie virali, su base esotossica, autoimmune, metabolica, fino allo stadio cirrotico, management di paziente con epatocarcinoma, paziente pre- e post -OLT), presso AST Ascoli Piceno- S.O. di San Benedetto del Tronto.

ABILITAZIONE SCIENTIFICA NAZIONALE:

Abilitazione Scientifica Nazionale alle funzioni di professore universitario di Seconda Fascia nel Settore Concorsuale 06/D4 - MALATTIE CUTANEE, MALATTIE INFETTIVE E MALATTIE DELL'APPARATO DIGERENTE dal 13-02-2023, valida per 11 anni.

Premi e riconoscimenti nazionali:

Vincitore del premio di ricerca della Società Italiana di Gastroenterologia come " best young researcher " nel 2006,2007, consegnati durante i congressi FISMAD di Napoli e Rimini, Italy.

Vincitore del premio di ricerca della della Società Italiana di Medicina Interna nel Novembre 2008 come " best young researcher ", consegnato durante il congresso nazionale S.I.M.I. di Genova del medesimo anno, Italy.

Vincitore del premio di ricerca " AISF investigator " nel 2010, consegnato durante il Congresso annuale, Univeristà La Sapienza, Roma, Italy.

Premi internazionali:

Premio di ricercar conseguito durante il meeting annuale della Federazione Europea di Gastroenterologia dell'Ottobre 2008, Vienna, Austria.

Premio come " Young Investigator " conseguito al Congresso annuale della società Internazionale di Neuro-Gastroenetrologia del 2009, Chicago, IL, USA.

Rome III Foundation International Research Fellowship, Chicago 2009.

Travel grant UEGW 2010, Barcelona, Spain. Best poster nominee.

Memberships:

Membro della Società Italiana di Gastroneterologia
Membro della Società Italiana di Medicina Interna
Membro della Federazione Europea di Gastroneterologia
Membro dell' American Gastroenterology Association.

Funzioni Editoriali:

Referee, Neurogastroenterology and Motility, dal 2008– oggi.
Referee, Digestive and Liver Disease, dal Marzo 2016-oggi.
Referee, United European Gastroenterology Journal, dal 2014-oggi.
Referee, Journal de Pediatria, dal Gennaio 2016-oggi.
Referee for Scientific Reports dal Maggio 2016-oggi
Referee for Acta Gastroenterologica Belgica, May 2016-present.
Referee for Carcinogenesis, da Aprile 2016-oggi.
Referee for Minerva Medica, da Maggio 2016-oggi.
Referee for Minerva Gastroenterologica and Dietologica, da Maggio 2016-oggi.
Referee for Minerva Pediatrica, da Maggio 2016-oggi.
Referee for the European Journal of Nutrition, da Settembre 2018-oggi.
Referee for Gastroenterology Research and practice, da Novembre 2018-oggi.
Referee for Medicines, da Gennaio 2021-oggi.
Referee for Nutrients, da Aprile 2020-oggi.
Referee for International Journal of Molecular Sciences, da Gennaio 2020-oggi.
Referee for Journal of Health Sciences, da Giugno 2021-oggi.
Referee for Expert Review of Clinical Immunology, da Settembre 2021-oggi.
Referee for Cells, January 2021-present.
Referee for The International Journal of Gastroenterology and Hepatology Diseases, da Settembre 2021-oggi.
Referee for Foods, da Gennaio 2020-oggi.
Referee for Biomedicines, da Giugno 2020-oggi.
Referee for Food Research International, da Gennaio 2020-oggi.
Editorial Board Member of The Scientific World Journal, da Agosto 2011-oggi.
Editorial Board Member of Review on Recent Clinical Trials, da Maggio 2016-oggi.
Editorial Board Member of Medicines, da Giugno 2021-oggi.
Editorial Board member di Hepatoma Research da Gennaio 2021 ad oggi.
Editorial Board member di Medicina da Giugno 2022 ad oggi.
Review Editor for Frontiers in Pharmacology, da Febbraio 2020-oggi.
Guest Editor for Frontiers in Pharmacology, Gastrointestinal and hepatic pharmacology, da Gennaio 2021-oggi.
Review Editor for Genes, da Marzo 2020-oggi.

Lingue:

Advanced knowledge of written and spoken English (level 7.5 as certified from British Council, Rome, Italy; IELTS exam undertaken on June 15 2016).

Good knowledge of written and spoken Dutch (level 2 out of 5, CLT, Leuven, Belgium).

Docenze

Professore a contratto in Anatomia umana dal Settembre 2022 ad oggi, presso il corso di Fisioterapia e Riabilitazione dell'Università Politecnica delle Marche, Ancona, sede di Ascoli Piceno.

Linee di ricerca ed interesse in corso:

- Studio delle malattie epatiche: steatosi epatica non alcolica, steatoepatite non alcolica e loro evoluzione verso cirrosi ed HCC;
- Studio del gut microbiota e suo ruolo nelle malattie metaboliche, : steatosi epatica non alcolica, steatoepatite non alcolica fino alla cirrosi e cancerogenesi;
- Nutrizione e suo impatto nelle malattie del tratto gastroenterico ed epatologico;
- Interazione tra COVID-19 e malattie epatiche;
- Regolazione di appetito e fame nell'ambito della Neurogastroenterologia.

PUBBLICAZIONI

Publications in international and national journals.

2005-23

H index 37; citations 5007. Media citazioni per articolo:52.7.
Impact factor totale: 699.112; impact factor medio per rivista: 8.035.

1: Montori M, Baroni GS, Santori P, Di Giampaolo C, Ponziani F, Abenavoli L, Scarpellini E. Liver Damage and COVID-19: At Least a "Two-Hit" Story in Systematic Review. *Curr Issues Mol Biol.* 2023 Apr 4;45(4):3035-3047. doi: 10.3390/cimb45040199. PMID: 37185723; PMCID: PMC10136465.

2: Balsiger LM, Carbone F, Raymenants K, Scarpellini E, Tack J. Understanding and managing patients with overlapping disorders of gut-brain interaction. *Lancet Gastroenterol Hepatol.* 2023 Apr;8(4):383-390. doi: 10.1016/S2468-1253(22)00435-6. Epub 2023 Jan 23. PMID: 36702144.

3: Boccuto L, Tack J, Ianiro G, Abenavoli L, Scarpellini E. Human Genes Involved in the Interaction between Host and Gut Microbiome: Regulation and Pathogenic Mechanisms. *Genes (Basel).* 2023 Mar 31;14(4):857. doi: 10.3390/genes14040857. PMID: 37107615; PMCID: PMC10137629.

4: Savytska M, Kozyk M, Strubchevska K, Yosypenko K, Falalyeyeva T, Kobylak N, Boccuto L, Pellicano R, Fagoonee S, Scarpellini E, Abenavoli L. Association between intestinal microflora and obesity. *Minerva Gastroenterol (Torino).* 2023 Mar 21. doi: 10.23736/S2724-5985.23.03379-X. Epub ahead of print. PMID: 36943206.

5: Abenavoli L, Scarlata GGM, Scarpellini E, Boccuto L, Spagnuolo R, Tilocca B,

Roncada P, Luzza F. Metabolic-Dysfunction-Associated Fatty Liver Disease and Gut Microbiota: From Fatty Liver to Dysmetabolic Syndrome. *Medicina (Kaunas)*. 2023 Mar 17;59(3):594. doi: 10.3390/medicina59030594. PMID: 36984595; PMCID: PMC10054528.

6: Scarcella M, Scarpellini E, Piergallini S, Rinninella E, Routhiaux K, Rasetti C, Abenavoli L, De Robertis E, Manzi P, Commissari R, Monti R, Zanetti M. Effect of Immuno-Nutrition on Malnutrition, Inflammatory Response and Clinical Course of Semi-Critically Ill COVID-19 Patients: A Pilot Perspective Study. *Nutrients*. 2023 Mar 2;15(5):1250. doi: 10.3390/nu15051250. PMID: 36904249; PMCID: PMC10004815.

7: Vitali M, Marasco S, Romenskaya T, Elia A, Longhitano Y, Zanza C, Abenavoli L, Scarpellini E, Bertuccio A, Barbanera A. Decompressive Craniectomy in Severe Traumatic Brain Injury: The Intensivist's Point of View. *Diseases*. 2023 Jan 30;11(1):22. doi: 10.3390/diseases11010022. PMID: 36810536; PMCID: PMC9944486.

8: Scarpellini E, Broeders B, Schol J, Santori P, Addarii M, Boccuto L, Carbone F, Abenavoli L, Tack J. The Use of Peppermint Oil in Gastroenterology. *Curr Pharm Des*. 2023;29(8):576-583. doi: 10.2174/1381612829666230328163449. PMID: 36994979.

9: Scarpellini E, Tack J. Post-COVID-19 Gastro-Intestinal Disturbances. *Rev Recent Clin Trials*. 2023;18(1):34-40. doi: 10.2174/1574887118666221201104833. PMID: 36464877.

10: Abenavoli L, Giubilei L, Procopio AC, Spagnuolo R, Luzza F, Boccuto L, Scarpellini E. Gut Microbiota in Non-Alcoholic Fatty Liver Disease Patients with Inflammatory Bowel Diseases: A Complex Interplay. *Nutrients*. 2022 Dec 15;14(24):5323. doi: 10.3390/nu14245323. PMID: 36558483; PMCID: PMC9785319.

11: Abenavoli L, Maurizi V, Boccuto L, Di Berardino A, Giostra N, Santori P, Scarcella ML, Procopio AC, Rasetti C, Scarpellini E. Nutritional Support in Acute Liver Failure. *Diseases*. 2022 Nov 18;10(4):108. doi: 10.3390/diseases10040108. PMID: 36412602; PMCID: PMC9680263.

12: Abenavoli L, Maurizi V, Rinninella E, Tack J, Di Berardino A, Santori P, Rasetti C, Procopio AC, Boccuto L, Scarpellini E. Fecal Microbiota Transplantation in NAFLD Treatment. *Medicina (Kaunas)*. 2022 Oct 30;58(11):1559. doi: 10.3390/medicina58111559. PMID: 36363516; PMCID: PMC9695159.

13: De Siena M, Raoul P, Costantini L, Scarpellini E, Cintoni M, Gasbarrini A, Rinninella E, Mele MC. Food Emulsifiers and Metabolic Syndrome: The Role of the Gut Microbiota. *Foods*. 2022 Jul 25;11(15):2205. doi: 10.3390/foods11152205. PMID: 35892789; PMCID: PMC9331555.

14: Mori H, Svegliati Baroni G, Marzoni M, Di Nicola F, Santori P, Maroni L, Abenavoli L, Scarpellini E. Farnesoid X Receptor, Bile Acid Metabolism, and Gut Microbiota. *Metabolites*. 2022 Jul 14;12(7):647. doi: 10.3390/metabo12070647. PMID: 35888771; PMCID: PMC9320384.

- 15: Scarpellini E, Abenavoli L, Cassano V, Rinninella E, Sorge M, Capretti F, Rasetti C, Svegliati Baroni G, Luzza F, Santori P, Sciacqua A. The Apparent Asymmetrical Relationship Between Small Bowel Bacterial Overgrowth, Endotoxemia, and Liver Steatosis and Fibrosis in Cirrhotic and Non-Cirrhotic Patients: A Single-Center Pilot Study. *Front Med (Lausanne)*. 2022 Apr 26;9:872428. doi: 10.3389/fmed.2022.872428. PMID: 35559337; PMCID: PMC9090439.
- 16: Scarpellini E, Balsiger LM, Maurizi V, Rinninella E, Gasbarrini A, Giostra N, Santori P, Abenavoli L, Rasetti C. Zinc and gut microbiota in health and gastrointestinal disease under the COVID-19 suggestion. *Biofactors*. 2022 Mar;48(2):294-306. doi: 10.1002/biof.1829. Epub 2022 Feb 26. PMID: 35218585; PMCID: PMC9082519.
- 17: Schol J, Carbone F, Holvoet L, Van den Houte K, Colomier E, Huang IH, Scarpellini E, Vanuytsel T, Tack J. Postinfectious onset in functional dyspepsia is a risk factor for weight loss. *J Gastroenterol*. 2022 Mar;57(3):156-163. doi: 10.1007/s00535-022-01854-y. Epub 2022 Jan 29. PMID: 35092499.
- 18: Scarcella M, Scarpellini E, Ascani A, Commissari R, Scorcella C, Zanetti M, Parisi A, Monti R, Milic N, Donati A, Luzza F, De Robertis E, Abenavoli L. Effect of Whey Proteins on Malnutrition and Extubating Time of Critically Ill COVID-19 Patients. *Nutrients*. 2022 Jan 19;14(3):437. doi: 10.3390/nu14030437. PMID: 35276795; PMCID: PMC8839228.
- 19: Scarpellini E, Ianiro G, Tack J. Editorial: Pharmacological Treatments Affecting Gastro-Intestinal Motility in Man. *Front Pharmacol*. 2022 Jan 19;12:801136. doi: 10.3389/fphar.2021.801136. PMID: 35126136; PMCID: PMC8807642.
- 20: Tkach S, Dorofeyev A, Kuzenko I, Boyko N, Falalyeyeva T, Boccuto L, Scarpellini E, Kobyljak N, Abenavoli L. Current Status and Future Therapeutic Options for Fecal Microbiota Transplantation. *Medicina (Kaunas)*. 2022 Jan 6;58(1):84. doi: 10.3390/medicina58010084. PMID: 35056392; PMCID: PMC8780626.
- 21: Scarpellini E, Rinninella E, Basilico M, Colomier E, Rasetti C, Larussa T, Santori P, Abenavoli L. From Pre- and Probiotics to Post-Biotics: A Narrative Review. *Int J Environ Res Public Health*. 2021 Dec 21;19(1):37. doi: 10.3390/ijerph19010037. PMID: 35010297; PMCID: PMC8750841.
- 22: Falalyeyeva T, Mamula Y, Scarpellini E, Leshchenko I, Humeniuk A, Pankiv I, Kobyljak N. Probiotics and obesity associated disease: an extended view beyond traditional strains. *Minerva Gastroenterol (Torino)*. 2021 Dec;67(4):348-356. doi: 10.23736/S2724-5985.21.02909-0. PMID: 35040301.
- 23: Abenavoli L, Scarpellini E, Luzza F. The role of gut microbiota in gastrointestinal diseases: the heart of the matter. *Minerva Gastroenterol (Torino)*. 2021 Dec;67(4):312-313. doi: 10.23736/S2724-5985.21.03022-9. PMID: 35040300.
- 24: Scarpellini E, Basilico M, Rinninella E, Carbone F, Schol J, Rasetti C, Abenavoli L, Santori P. Probiotics and gut health. *Minerva Gastroenterol (Torino)*. 2021 Dec;67(4):314-325. doi: 10.23736/S2724-5985.21.02910-7. Epub 2021

May 12. PMID: 33978391.

25: Abenavoli L, Procopio AC, Scarpellini E, Polimeni N, Aquila I, Larussa T, Boccuto L, Luzza F. Gut microbiota and non-alcoholic fatty liver disease. *Minerva Gastroenterol (Torino)*. 2021 Dec;67(4):339-347. doi: 10.23736/S2724-5985.21.02896-5. Epub 2021 Apr 19. PMID: 33871224.

26: Di Geso L, Rasetti C, Pellegrini D, Collina G, D'Angelo A, Corradini D, De Benedictis MG, Gismondi M, Lattanzi E, Scarpellini E, Santori P. A Histologically Positive Giant Cell Arteritis After a 6-Week Glucocorticoid Treatment: A Case Report. *J Clin Rheumatol*. 2021 Dec 1;27(8S):S773-S774. doi: 10.1097/RHU.0000000000001491. PMID: 32701536.

27: Tack J, Verbeure W, Mori H, Schol J, Van den Houte K, Huang IH, Balsiger L, Broeders B, Colomier E, Scarpellini E, Carbone F. The gastrointestinal tract in hunger and satiety signalling. *United European Gastroenterol J*. 2021 Jul;9(6):727-734. doi: 10.1002/ueg2.12097. Epub 2021 Jun 21. PMID: 34153172; PMCID: PMC8280794.

28: Scarpellini E, Van den Houte K, Schol J, Huang IH, Colomier E, Carbone F, Tack J. Nutrient Drinking Test as Biomarker in Functional Dyspepsia. *Am J Gastroenterol*. 2021 Jul 1;116(7):1387-1395. doi: 10.14309/ajg.0000000000001242. PMID: 33941747.

29: Abenavoli L, Boccuto L, Scarpellini E. Are probiotics effective in reversing non-alcoholic steatohepatitis? *Hepatobiliary Surg Nutr*. 2021 Jun;10(3):407-409. doi: 10.21037/hbsn-21-85. PMID: 34159177; PMCID: PMC8188124.

30: Scarpellini E, Arts J, Vanuytsel T, Tack J. Reply to: Late dumping syndrome or postprandial reactive hypoglycaemic syndrome after bariatric surgery. *Nat Rev Endocrinol*. 2021 May;17(5):317-318. doi: 10.1038/s41574-021-00474-5. PMID: 33536608.

31: Sarno G, Montalti R, Giglio MC, Rompianesi G, Tomassini F, Scarpellini E, De Simone G, De Palma GD, Troisi RI. Hepatocellular carcinoma in patients with chronic renal disease: Challenges of interventional treatment. *Surg Oncol*. 2021 Mar;36:42-50. doi: 10.1016/j.suronc.2020.11.007. Epub 2020 Nov 20. PMID: 33307490.

32: Kulanthaivel S, Kaliberdenko VB, Balasundaram K, Shterenshis MV, Scarpellini E, Abenavoli L. Tocilizumab in SARS-CoV-2 Patients with the Syndrome of Cytokine Storm: A Narrative Review. *Rev Recent Clin Trials*. 2021;16(2):138-145. doi: 10.2174/1574887115666200917110954. PMID: 32940187.

33: Abenavoli L, Scarpellini E, Pellicano R, Fagoonee S, Larussa T, Luzza F. Mediterranean diet and probiotics supplementation to treat non-alcoholic fatty liver disease. *Minerva Med*. 2020 Dec;111(6):526-528. doi: 10.23736/S0026-4806.20.07089-5. Epub 2020 Nov 3. PMID: 33140925.

34: Scarpellini E, Fagoonee S, Rinninella E, Rasetti C, Aquila I, Larussa T, Ricci P, Luzza F, Abenavoli L. Gut Microbiota and Liver Interaction through

Immune System Cross-Talk: A Comprehensive Review at the Time of the SARS-CoV-2 Pandemic. *J Clin Med*. 2020 Aug 3;9(8):2488. doi: 10.3390/jcm9082488. PMID: 32756323; PMCID: PMC7464500.

35: Scarpellini E, Arts J, Karamanolis G, Laurenus A, Siquini W, Suzuki H, Ukleja A, Van Beek A, Vanuytsel T, Bor S, Ceppa E, Di Lorenzo C, Emous M, Hammer H, Hellström P, Laville M, Lundell L, Masclee A, Ritz P, Tack J. International consensus on the diagnosis and management of dumping syndrome. *Nat Rev Endocrinol*. 2020 Aug;16(8):448-466. doi: 10.1038/s41574-020-0357-5. Epub 2020 May 26. PMID: 32457534; PMCID: PMC7351708.

36: Tack J, Schol J, Geeraerts A, Huang IH, Mori H, Scarpellini E, Sinonquel P, Carbone F, Colomier E, Geysen H, Jandee S, Moonen A, Pannemans J, Timmermans L, Van den Houte K, Verbeure W, Wauters L, Bisschops R, Hoffman I, Roelandt P, Rommel N, Simren M, Suzuki H, Tornblom H, Verbeke K, Vanuytsel T. A survey on the impact of the COVID-19 pandemic on motility and functional investigations in Europe and considerations for recommencing activities in the early recovery phase. *Neurogastroenterol Motil*. 2020 Jul;32(7):e13926. doi: 10.1111/nmo.13926. PMID: 32478910; PMCID: PMC7300498.

37: Van den Houte K, Scarpellini E, Verbeure W, Mori H, Schol J, Masuy I, Carbone F, Tack J. The Role of GI Peptides in Functional Dyspepsia and Gastroparesis: A Systematic Review. *Front Psychiatry*. 2020 Mar 18;11:172. doi: 10.3389/fpsy.2020.00172. PMID: 32256403; PMCID: PMC7093580.

38: Stracci G, Scarpellini E, Rinninella E, Mignini EV, Clementi N, Boni MV, Valeri MV, Sansoni D, Abenavoli L, Gasbarrini A, Rasetti C, Santori P. Effects of enteral nutrition on patients with pressure lesions: a single center, pilot study. *Eur Rev Med Pharmacol Sci*. 2020 Feb;24(3):1563-1570. doi: 10.26355/eurrev_202002_20214. PMID: 32096205.

39: Méndez-Sánchez N, Valencia-Rodriguez A, Vera-Barajas A, Abenavoli L, Scarpellini E, Ponciano-Rodriguez G, Wang DQ. The mechanism of dysbiosis in alcoholic liver disease leading to liver cancer. *Hepatoma Res*. 2020;6:5. doi: 10.20517/2394-5079.2019.29. Epub 2020 Feb 20. PMID: 32582865; PMCID: PMC7313221.

40: Scarpellini E, Luigiano C, Svegliati-Baroni G, Dumitrascu D, Larussa T, Santori V, Luzzza F, Abenavoli L. Liver Cirrhosis Complications Management at the Emergency Department. *Rev Recent Clin Trials*. 2020;15(4):331-338. doi: 10.2174/1574887115666200603160816. PMID: 32493202.

41: Abenavoli L, Scarpellini E, Colica C, Boccuto L, Salehi B, Sharifi-Rad J, Aiello V, Romano B, De Lorenzo A, Izzo AA, Capasso R. Gut Microbiota and Obesity: A Role for Probiotics. *Nutrients*. 2019 Nov 7;11(11):2690. doi: 10.3390/nu11112690. PMID: 31703257; PMCID: PMC6893459.

42: Dallio M, Diano N, Masarone M, Gravina AG, Patanè V, Romeo M, Di Sarno R, Errico S, Nicolucci C, Abenavoli L, Scarpellini E, Boccuto L, Persico M, Loguercio C, Federico A. Chemical Effect of Bisphenol A on Non-Alcoholic Fatty Liver Disease. *Int J Environ Res Public Health*. 2019 Aug 28;16(17):3134. doi:

10.3390/ijerph16173134. PMID: 31466361; PMCID: PMC6747307.

43: Scarpellini E, Deloose E, Vos R, Francois I, Delcour JA, Broekaert WF, Verbeke K, Tack J. The effect of arabinoxylooligosaccharides on upper gastroduodenal motility and hunger ratings in humans. *Neurogastroenterol Motil.* 2018 Jul;30(7):e13306. doi: 10.1111/nmo.13306. Epub 2018 Feb 13. PMID: 29436142.

44: Mignini EV, Scarpellini E, Rinninella E, Lattanzi E, Valeri MV, Clementi N, Abenavoli L, Gasbarrini A, Rasetti C, Santori P. Impact of patients nutritional status on major surgery outcome. *Eur Rev Med Pharmacol Sci.* 2018 Jun;22(11):3524-3533. doi: 10.26355/eurrev_201806_15179. PMID: 29917207.

45: Preveden T, Scarpellini E, Milić N, Luzza F, Abenavoli L. Gut microbiota changes and chronic hepatitis C virus infection. *Expert Rev Gastroenterol Hepatol.* 2017 Sep;11(9):813-819. doi: 10.1080/17474124.2017.1343663. Epub 2017 Jun 23. PMID: 28621554.

46: Scarpellini E, Pauwels A, Vos R, Rommel N, Tack J. Effect of methylnaltrexone and naloxone on esophageal motor function in man. *Neurogastroenterol Motil.* 2017 Mar;29(3). doi: 10.1111/nmo.12938. Epub 2017 Jan 22. PMID: 28110513.

47: Scarpellini E, Boecxstaens V, Broers C, Vos R, Pauwels A, Tack J. Effect of baclofen on gastric acid pocket in subjects with gastroesophageal reflux disease symptoms. *Dis Esophagus.* 2016 Nov;29(8):1054-1063. doi: 10.1111/dote.12443. Epub 2015 Nov 6. PMID: 26541138.

48: Scarpellini E, Deloose E, Vos R, Francois IE, Delcour JA, Broekaert WF, Verbeke K, Tack J. The effect of arabinoxylooligosaccharides on gastric sensory-motor function and nutrient tolerance in man. *Neurogastroenterol Motil.* 2016 Aug;28(8):1194-203. doi: 10.1111/nmo.12819. Epub 2016 May 20. PMID: 27206549.

49: Scarpellini E, Laterza L, Ianiro G, Tack J, Abenavoli L, Gasbarrini A. Eluxadoline for the treatment of diarrhoea-predominant irritable bowel syndrome. *Expert Opin Pharmacother.* 2016 Jul;17(10):1395-402. doi: 10.1080/14656566.2016.1182982. Epub 2016 Jun 8. PMID: 27267380.

50: Scarpellini E, Ang D, Pauwels A, De Santis A, Vanuytsel T, Tack J. Management of refractory typical GERD symptoms. *Nat Rev Gastroenterol Hepatol.* 2016 May;13(5):281-94. doi: 10.1038/nrgastro.2016.50. Epub 2016 Apr 14. PMID: 27075264.

51: Tack J, Deloose E, Ang D, Scarpellini E, Vanuytsel T, Van Oudenhove L, Depoortere I. Motilin-induced gastric contractions signal hunger in man. *Gut.* 2016 Feb;65(2):214-24. doi: 10.1136/gutjnl-2014-308472. Epub 2014 Dec 24. PMID: 25539673.

52: Scarpellini E, Forlino M, Lupo M, Rasetti C, Fava G, Abenavoli L, De Santis A. Gut Microbiota and Alcoholic Liver Disease. *Rev Recent Clin Trials.* 2016;11(3):213-9. doi: 10.2174/1574887111666160810100538. PMID: 27515958.

- 53: Scarpellini E, Ianiro G, Attili F, Bassanelli C, De Santis A, Gasbarrini A. The human gut microbiota and virome: Potential therapeutic implications. *Dig Liver Dis.* 2015 Dec;47(12):1007-12. doi: 10.1016/j.dld.2015.07.008. Epub 2015 Jul 18. PMID: 26257129; PMCID: PMC7185617.
- 54: Scarpellini E, Boecxstaens V, Farré R, Bisschops R, Dewulf D, Gasbarrini A, Pauwels A, Blondeau K, Tack J. Effect of baclofen on the acid pocket at the gastroesophageal junction. *Dis Esophagus.* 2015 Jul;28(5):488-95. doi: 10.1111/dote.12224. Epub 2014 Apr 24. PMID: 24758736.
- 55: Iannucci G, Scarpellini E, Balsano C, Paroli M, Leone G, Giannoni MF. Could monitoring normotensives delay progression to hypertension? *Eur Rev Med Pharmacol Sci.* 2014 Jun;18(11):1680-1. PMID: 24943983.
- 56: Scarpellini E, Lupo M, Iegri C, Gasbarrini A, De Santis A, Tack J. Intestinal permeability in non-alcoholic fatty liver disease: the gut-liver axis. *Rev Recent Clin Trials.* 2014;9(3):141-7. doi: 10.2174/1574887109666141216104334. PMID: 25514911.
- 57: Iannucci G, Balsano C, Paroli M, Scarpellini E, Leone G, Giannoni MF. Office normotensives with a minimal augmentation of intima-media thickness of common carotid arteries: really normotensives? *Eur Rev Med Pharmacol Sci.* 2013 Dec;17(23):3164-8. PMID: 24338457.
- 58: Savarino E, Mei F, Parodi A, Ghio M, Furnari M, Gentile A, Berdini M, Di Sario A, Bendia E, Bonazzi P, Scarpellini E, Laterza L, Savarino V, Gasbarrini A. Gastrointestinal motility disorder assessment in systemic sclerosis. *Rheumatology (Oxford).* 2013 Jun;52(6):1095-100. doi: 10.1093/rheumatology/kes429. Epub 2013 Feb 4. PMID: 23382360.
- 59: Scarpellini E, Giorgio V, Gabrielli M, Filoni S, Vitale G, Tortora A, Ojetti V, Gigante G, Fundarò C, Gasbarrini A. Rifaximin treatment for small intestinal bacterial overgrowth in children with irritable bowel syndrome. *Eur Rev Med Pharmacol Sci.* 2013 May;17(10):1314-20. PMID: 23740443.
- 60: Abenavoli L, Scarpellini E, Rouabhia S, Balsano C, Lizza F. Probiotics in non-alcoholic fatty liver disease: which and when. *Ann Hepatol.* 2013 May-Jun;12(3):357-63. PMID: 23619251.
- 61: Purchiaroni F, Tortora A, Gabrielli M, Bertucci F, Gigante G, Ianiro G, Ojetti V, Scarpellini E, Gasbarrini A. The role of intestinal microbiota and the immune system. *Eur Rev Med Pharmacol Sci.* 2013 Feb;17(3):323-33. PMID: 23426535.
- 62: Scarpellini E, Abenavoli L, Balsano C, Gabrielli M, Lizza F, Tack J. Breath tests for the assessment of the orocecal transit time. *Eur Rev Med Pharmacol Sci.* 2013;17 Suppl 2:39-44. PMID: 24443067.
- 63: Gabrielli M, D'Angelo G, Di Rienzo T, Scarpellini E, Ojetti V. Diagnosis of small intestinal bacterial overgrowth in the clinical practice. *Eur Rev Med Pharmacol Sci.* 2013;17 Suppl 2:30-5. PMID: 24443065.

- 64: Tortora A, Purchiaroni F, Scarpellini E, Ojetti V, Gabrielli M, Vitale G, Giovanni G, Gasbarrini A. Colitides. *Eur Rev Med Pharmacol Sci*. 2012 Nov;16(13):1795-805. PMID: 23208963.
- 65: Scarpellini E, Cafarotti S, Cesario A, Lococo F, Margaritora S, Gabrielli M, Tortora A, Gasbarrini A, Granone P. A case of vomiting in an anorexic achalasic patient. *Eur Rev Med Pharmacol Sci*. 2012 Oct;16 Suppl 4:44-7. PMID: 23090806.
- 66: Scarpellini E, Tack J. Food allergy: from diagnosis to treatment. *Dig Dis*. 2012;30(2):224-31. doi: 10.1159/000336709. Epub 2012 Jun 20. PMID: 22722444.
- 67: Scarpellini E, Tack J. Obesity and metabolic syndrome: an inflammatory condition. *Dig Dis*. 2012;30(2):148-53. doi: 10.1159/000336664. Epub 2012 Jun 20. PMID: 22722429.
- 68: Omari TI, Papathanasopoulos A, Dejaeger E, Wauters L, Scarpellini E, Vos R, Sloopmaekers S, Seghers V, Cornelissen L, Goeleven A, Tack J, Rommel N. Reproducibility and agreement of pharyngeal automated impedance manometry with videofluoroscopy. *Clin Gastroenterol Hepatol*. 2011 Oct;9(10):862-7. doi: 10.1016/j.cgh.2011.05.026. Epub 2011 Jun 6. PMID: 21699810.
- 69: Gasbarrini A, Scarpellini E, Gabrielli M, Tortora A, Purchiaroni F, Ojetti V. Clinical predictors of small intestinal bacterial overgrowth by duodenal aspirate culture. *Aliment Pharmacol Ther*. 2011 Jun;33(12):1378-9; author reply 1379-80. doi: 10.1111/j.1365-2036.2011.04657.x. PMID: 21569063.
- 70: Boecxstaens V, Bisschops R, Blondeau K, Vos R, Scarpellini E, De Wulf D, Tack J. Modulation of the postprandial acid and bile pockets at the gastro-oesophageal junction by drugs that affect gastric motility. *Aliment Pharmacol Ther*. 2011 Jun;33(12):1370-7. doi: 10.1111/j.1365-2036.2011.04664.x. Epub 2011 Apr 24. PMID: 21517922.
- 71: Gabrielli M, Bonazzi P, Scarpellini E, Bendia E, Lauritano EC, Fasano A, Ceravolo MG, Capecchi M, Rita Bentivoglio A, Provinciali L, Tonali PA, Gasbarrini A. Prevalence of small intestinal bacterial overgrowth in Parkinson's disease. *Mov Disord*. 2011 Apr;26(5):889-92. doi: 10.1002/mds.23566. Epub 2011 Feb 1. PMID: 21520278.
- 72: Scarpellini E, Blondeau K, Boecxstaens V, Vos R, Gasbarrini A, Farré R, Tack J. Effect of rimonabant on oesophageal motor function in man. *Aliment Pharmacol Ther*. 2011 Mar;33(6):730-7. doi: 10.1111/j.1365-2036.2011.04576.x. Epub 2011 Jan 20. PMID: 21251031.
- 73: Gigante G, Tortora A, Ianiro G, Ojetti V, Purchiaroni F, Campanale M, Cesario V, Scarpellini E, Gasbarrini A. Role of gut microbiota in food tolerance and allergies. *Dig Dis*. 2011;29(6):540-9. doi: 10.1159/000332977. Epub 2011 Dec 12. PMID: 22179209.
- 74: Scarpellini E, Vos R, Blondeau K, Boecxstaens V, Farré R, Gasbarrini A, Tack J. The effects of itopride on oesophageal motility and lower oesophageal

- sphincter function in man. *Aliment Pharmacol Ther.* 2011 Jan;33(1):99-105. doi: 10.1111/j.1365-2036.2010.04487.x. Epub 2010 Oct 18. PMID: 21083582.
- 75: Scarpellini E, Campanale M, Leone D, Purchiaroni F, Vitale G, Lauritano EC, Gasbarrini A. Gut microbiota and obesity. *Intern Emerg Med.* 2010 Oct;5 Suppl 1:S53-6. doi: 10.1007/s11739-010-0450-1. PMID: 20865475.
- 76: Lauritano EC, Valenza V, Sparano L, Scarpellini E, Gabrielli M, Cazzato A, Ferraro PM, Gasbarrini A. Small intestinal bacterial overgrowth and intestinal permeability. *Scand J Gastroenterol.* 2010 Sep;45(9):1131-2. doi: 10.3109/00365521.2010.485325. PMID: 20443749.
- 77: Ameloot K, Janssen P, Scarpellini E, Vos R, Boesmans W, Depoortere I, Vanden Berghe P, Tack J. Endocannabinoid control of gastric sensorimotor function in man. *Aliment Pharmacol Ther.* 2010 May;31(10):1123-31. doi: 10.1111/j.1365-2036.2010.04259.x. Epub 2010 Feb 8. PMID: 20146701.
- 78: Scarpellini E, Valenza V, Gabrielli M, Lauritano EC, Perotti G, Merra G, Dal Lago A, Ojetti V, Ainora ME, Santoro M, Ghirlanda G, Gasbarrini A. Intestinal permeability in cirrhotic patients with and without spontaneous bacterial peritonitis: is the ring closed? *Am J Gastroenterol.* 2010 Feb;105(2):323-7. doi: 10.1038/ajg.2009.558. Epub 2009 Oct 20. PMID: 19844200.
- 79: Ojetti V, Pitocco D, Scarpellini E, Zaccardi F, Scaldaferri F, Gigante G, Gasbarrini G, Ghirlanda G, Gasbarrini A. Small bowel bacterial overgrowth and type 1 diabetes. *Eur Rev Med Pharmacol Sci.* 2009 Nov-Dec;13(6):419-23. PMID: 20085122.
- 80: Scarpellini E, Gabrielli M, Za T, Lauritano EC, Santoliquido A, Rossi E, Ojetti V, Cammarota G, De Stefano V, Gasbarrini A. The interaction between small intestinal bacterial overgrowth and warfarin treatment. *Am J Gastroenterol.* 2009 Sep;104(9):2364-5. doi: 10.1038/ajg.2009.288. PMID: 19727103.
- 81: Scarpellini E, Giorgio V, Gabrielli M, Lauritano EC, Pantanella A, Fundarò C, Gasbarrini A. Prevalence of small intestinal bacterial overgrowth in children with irritable bowel syndrome: a case-control study. *J Pediatr.* 2009 Sep;155(3):416-20. doi: 10.1016/j.jpeds.2009.03.033. Epub 2009 Jun 16. PMID: 19535093.
- 82: Gabrielli M, Lauritano EC, Scarpellini E, Lupascu A, Ojetti V, Gasbarrini G, Silveri NG, Gasbarrini A. *Bacillus clausii* as a treatment of small intestinal bacterial overgrowth. *Am J Gastroenterol.* 2009 May;104(5):1327-8. doi: 10.1038/ajg.2009.91. Epub 2009 Apr 7. PMID: 19352343.
- 83: Lauritano EC, Gabrielli M, Scarpellini E, Ojetti V, Roccarina D, Villita A, Fiore E, Flore R, Santoliquido A, Tondi P, Gasbarrini G, Ghirlanda G, Gasbarrini A. Antibiotic therapy in small intestinal bacterial overgrowth: rifaximin versus metronidazole. *Eur Rev Med Pharmacol Sci.* 2009 Mar-Apr;13(2):111-6. PMID: 19499846.
- 84: Scarpellini E, Tack J. Renzapride: a new drug for the treatment of

constipation in the irritable bowel syndrome. *Expert Opin Investig Drugs*. 2008 Nov;17(11):1663-70. doi: 10.1517/13543784.17.11.1663. PMID: 18922103.

85: Lauritano EC, Gabrielli M, Scarpellini E, Lupascu A, Novi M, Sottili S, Vitale G, Cesario V, Serricchio M, Cammarota G, Gasbarrini G, Gasbarrini A. Small intestinal bacterial overgrowth recurrence after antibiotic therapy. *Am J Gastroenterol*. 2008 Aug;103(8):2031-5. doi: 10.1111/j.1572-0241.2008.02030.x. PMID: 18802998.

86: Montalto M, Santoro L, Dalvai S, Curigliano V, D'Onofrio F, Scarpellini E, Cammarota G, Panunzi S, Gallo A, Gasbarrini A, Gasbarrini G. Fecal calprotectin concentrations in patients with small intestinal bacterial overgrowth. *Dig Dis*. 2008;26(2):183-6. doi: 10.1159/000116777. Epub 2008 Apr 21. PMID: 18431069.

87: Scarpellini E, Cazzato A, Lauritano C, Gabrielli M, Lupascu A, Gerardino L, Abenavoli L, Petruzzellis C, Gasbarrini G, Gasbarrini A. Probiotics: which and when? *Dig Dis*. 2008;26(2):175-82. doi: 10.1159/000116776. Epub 2008 Apr 21. PMID: 18431068.

88: Ojetti V, Gabrielli M, Migneco A, Lauritano C, Zocco MA, Scarpellini E, Nista EC, Gasbarrini G, Gasbarrini A. Regression of lactose malabsorption in coeliac patients after receiving a gluten-free diet. *Scand J Gastroenterol*. 2008;43(2):174-7. doi: 10.1080/00365520701676138. PMID: 17917999.

89: Franceschi F, Cazzato A, Nista EC, Scarpellini E, Roccarina D, Gigante G, Gasbarrini G, Gasbarrini A. Role of probiotics in patients with *Helicobacter pylori* infection. *Helicobacter*. 2007 Nov;12 Suppl 2:59-63. doi: 10.1111/j.1523-5378.2007.00565.x. PMID: 17991178.

90: Lauritano EC, Bilotta AL, Gabrielli M, Scarpellini E, Lupascu A, Laginestra A, Novi M, Sottili S, Serricchio M, Cammarota G, Gasbarrini G, Pontecorvi A, Gasbarrini A. Association between hypothyroidism and small intestinal bacterial overgrowth. *J Clin Endocrinol Metab*. 2007 Nov;92(11):4180-4. doi: 10.1210/jc.2007-0606. Epub 2007 Aug 14. PMID: 17698907.

91: Scarpellini E, Gabrielli M, Lauritano CE, Lupascu A, Merra G, Cammarota G, Cazzato IA, Gasbarrini G, Gasbarrini A. High dosage rifaximin for the treatment of small intestinal bacterial overgrowth. *Aliment Pharmacol Ther*. 2007 Apr 1;25(7):781-6. doi: 10.1111/j.1365-2036.2007.03259.x. PMID: 17373916.

92: Gasbarrini A, Lauritano EC, Gabrielli M, Scarpellini E, Lupascu A, Ojetti V, Gasbarrini G. Small intestinal bacterial overgrowth: diagnosis and treatment. *Dig Dis*. 2007;25(3):237-40. doi: 10.1159/000103892. PMID: 17827947.

93: Lupascu A, Gabrielli M, Lauritano EC, Scarpellini E, Santoliquido A, Cammarota G, Flore R, Tondi P, Pola P, Gasbarrini G, Gasbarrini A. Hydrogen glucose breath test to detect small intestinal bacterial overgrowth: a prevalence case-control study in irritable bowel syndrome. *Aliment Pharmacol Ther*. 2005 Dec;22(11-12):1157-60. doi: 10.1111/j.1365-2036.2005.02690.x. PMID: 16305730.

94: Lauritano EC, Gabrielli M, Lupascu A, Santoliquido A, Nucera G, Scarpellini E, Vincenti F, Cammarota G, Flore R, Pola P, Gasbarrini G, Gasbarrini A. Rifaximin dose-finding study for the treatment of small intestinal bacterial overgrowth. *Aliment Pharmacol Ther.* 2005 Jul 1;22(1):31-5. doi: 10.1111/j.1365-2036.2005.02516.x. PMID: 15963077.

CAPITOLI DI LIBRI:

TRATTATO DI MEDICINA INTERNA (INTERNAL MEDICINE MANUAL) PROF. G.B. GASBARRINI, VERDUCI editore: CAPITOLI: DISPEPSIA; METEOSIMO INTESTINALE. SINDROMI POSTGASTRECTOMIA. Siquini W, Felicioni F, Scarpellini E. *Manuale di Chirurgia Generale*, D.G. D'Amico, Piccin Editore, August the 30th 2018 (Italian).

Presentations at National and International Meetings:

1. Meeting (Italian) **“Nuove terapie biologiche in Medicina Interna: cellule staminali e citochine/anti-citochine”**. December 5 2002, Università Cattolica del S. Cuore, Facoltà di Medicina e Chirurgia, Policlinico Gemelli, UCSC, Rome;
2. Meeting (Italian): **“Aterotrombosi 2003 focus su prevenzione primaria”**, May 8-9 2003, Università Cattolica del S. Cuore, Facoltà di Medicina e Chirurgia, Rome;
3. Meeting (Italian): **“Nuove metodiche diagnostico-terapeutiche in gastroenterologia”**, June 5-6 2003; Università Cattolica del S. Cuore, Facoltà di Medicina e Chirurgia, Rome;
4. **Simposium (italian): “Malattie infiammatorie croniche intestinali”**, Università Cattolica del S. Cuore, Facoltà di Medicina e Chirurgia, Rome, June 26, 2003
5. Meeting (Italian): **FONCRE (Forza Operativa per la diagnosi, la prevenzione e la terapia del cancro del colon retto): “Neoplasie del colon-retto: dalla prevenzione alla terapia”**; November 14, 2003, Università Cattolica del S. Cuore, Facoltà di Medicina e Chirurgia Rome, Policlinico Gemelli;
6. Meeting (Italian): **Convegno Nazionale della società Italiana di Ematologia e della Società Italiana di Medicina Trasfusionale e Immunoematologia: “una banca di cellule staminali somatiche per le malattie ematologiche ed oltre”**;

Università Cattolica del S. Cuore, Facoltà di Medicina e Chirurgia, Rome, Policlinico Gemelli, December 15, 2003;

7. Meeting (Italian): **V Simposio Nazionale di genetica molecolare clinica e molecolare**, Università Cattolica del S. Cuore, Facoltà di Medicina e Chirurgia, Rome, May 22 2004.
8. Meeting (Italian): **Congresso “Patologie vascolari negli atleti”**, UCSC, Istituto di Medicina Interna e Geriatria, May 2004, Rome;
9. Meeting (Italian): **Congresso: “La nuova Angiologia” – I° International Meeting on Recent Advancement in vascular Medicine**; Università Cattolica del S. Cuore, Facoltà di Medicina e Chirurgia, Rome, Policlinico Gemelli, February 5-6 2004;
10. Meeting (Italian): **Convegno su “ Probiotici e Prebiotici”** Hotel Pineta Palace , October 9 2004, Rome;
11. Meeting (Italian): **I° CORSO NAZIONALE DI FORMAZIONE SUL MORBO CELIACO**, Rome, Università di Tor Vergata, October 16 2004;
12. Meeting (Italian): **FROM BENCH TO BESIDE, I° Meeting sulla ricerca italiana 2004 nelle IBD**, November 15, 2004, Rome, Policlinico A. Gemelli;
13. Meeting (Italian): **Attualità diagnostico-terapeutiche in Gastroenterologia ed Epatologia**, Rome, November 16-17 2004, Aula Brasca del Policlinico A. Gemelli;
14. Meeting (Italian): **IL FEGATO GRASSO NELLA PRATICA CLINICA**, January 28 2005, Aula Brasca, Policlinico Gemelli, Rome;
15. Meeting (Italian): **VII CONVEGNO NAZIONALE DI GENETICA CLINICA**, February 21-22 2005, aula Brasca , Policlinico Gemelli, Rome;

16. **National Meeting of the Italian Society of Internal Medicine: S.I.M.I. 2005**, October 17-21. Hilton Hotel. Rome;
17. **National Meeting of the Italian Society of Gastroenterology: SIGE 2006. Naples, April 1-5 2006. Centro congressi “ Mostra d’oltremare ”** ; Oral communication: “ Role of Bacillus Clausii on Small Intestinal Bacterial Overgrowth “.
18. **DDW 2006**. May 19-25 ,Los Angeles (US).
19. **European Helicobacter Study Group Meeting: EHSG 2006**. September 7-9, Breslavia (PO); Oral communication: “ Effect of Butyric acid and inulin on side-effects of anti-H. Piloni antibiotic therapy: preliminary data “.
20. **DDW 2007. May 19-24 Washington DC (USA)**; Poster: “ **HIGH DOSAGE RIFAXIMIN FOR THE TREATMENT OF SMALL INTESTINAL BACTERIAL OVERGROWTH** “.
21. **National Meeting of the Italian Society of Gastroenterology: SIGE 2007. September 29 – October 3, 2007, Palermo, Fiera del Mediterraneo**. Abstracts-Posters: **HIGH DOSAGE RIFAXIMIN FOR THE TREATMENT OF SMALL INTESTINAL BACTERIAL OVERGROWTH; BUTHYRIC ACID AND INULIN: NOVEL TREATMENT OPTIONS IN IBS PATIENTS; SMALL INTESTINAL BACTERIAL OVERGROWTH AND ORAL ANTICOAGULANT THERAPY; SMALL INTESTINAL BACTERIAL OVERGROWTH RECURRENCE; RIFAXIMIN VERSUS SYSTEMIC ANTIBIOTICS IN SIBO TREATMENT**.
22. **National Meeting of the Italian Society of Gastroenterology: SIGE 2008: March 8-12, Rimini – Fiera**. Two oral communications: **⁵¹Cr-EDTA PERMEABILITY TEST IN ASCITIC CIRRHOTIC PATIENTS WITH AND WITHOUT HISTORY OF SPONTANEOUS BACTERIAL PERITONITIS; SMALL INTESTINAL BACTERIAL OVERGROWTH IN A IRRITABLE BOWEL SYNDROME CHILDREN POPULATION: A CASE-CONTROL STUDY; 2 POSTER: INTESTINAL**

PERMEABILITY IN MIGRAINEURS; SMALL INTESTINAL BACTERIAL OVERGROWTH OF COLONIC-TYPE CARBOHIDRATES FERMENTATIVE BACTERIA IN CIRRHOTIC PATIENTS.

23. **European Federation of Internal Medicine Meeting: EFIM Rome, May 5-8, 2008:**
3 Posters: **⁵¹Cr-EDTA PERMEABILITY TEST IN ASCITIC CIRRHOTIC PATIENTS WITH AND WITHOUT HISTORY OF SPONTANEOUS BACTERIAL PERITONITIS; INTESTINAL PERMEABILITY IN MIGRAINEURS; SMALL INTESTINAL BACTERIAL OVERGROWTH OF COLONIC-TYPE CARBOHIDRATES FERMENTATIVE BACTERIA IN CIRRHOTIC PATIENTS.**
24. **Meeting of the European Association for the study of the liver: EASL. Milan, April 28-29, 2008;** 2 Poster: **⁵¹Cr-EDTA PERMEABILITY TEST IN ASCITIC CIRRHOTIC PATIENTS WITH AND WITHOUT HISTORY OF SPONTANEOUS BACTERIAL PERITONITIS; SMALL INTESTINAL BACTERIAL OVERGROWTH OF COLONIC-TYPE CARBOHIDRATES FERMENTATIVE BACTERIA IN CIRRHOTIC PATIENTS.**
25. **DDW 2008 San Diego 2008:** May 17-22, San Diego Convention Center: Posters: **⁵¹Cr-EDTA PERMEABILITY TEST IN ASCITIC CIRRHOTIC PATIENTS WITH AND WITHOUT HISTORY OF SPONTANEOUS BACTERIAL PERITONITIS; INTESTINAL PERMEABILITY IN MIGRAINEURS; SMALL INTESTINAL BACTERIAL OVERGROWTH OF COLONIC-TYPE CARBOHIDRATES FERMENTATIVE BACTERIA IN CIRRHOTIC PATIENTS; SMALL INTESTINAL BACTERIAL OVERGROWTH AND ORAL ANTICOAGULANT THERAPY; SMALL INTESTINAL BACTERIAL OVERGROWTH RECURRENCE; RIFAXIMIN VERSUS SYSTEMIC ANTIBIOTICS IN SIBO TREATMENT .**
26. **EUROPEAN THORACIC SURGEONS CONGRESS: June 11 2008, Bologna, Palazzo Re Enzo:** Lecture: “ New insights in the pathophysiology of primary esophageal diseases “.
27. **United European Gastroenterology week: UEGW 2008, Wien, October 18-22, 2008.** Oral communication: **INTESTINAL PERMEABILITY IN MIGRAINEURS.**

Posters: ⁵¹Cr-EDTA PERMEABILITY TEST IN ASCITIC CIRRHOTIC PATIENTS WITH AND WITHOUT HISTORY OF SPONTANEOUS BACTERIAL PERITONITIS; SMALL INTESTINAL BACTERIAL OVERGROWTH OF COLONIC-TYPE CARBOHIDRATES FERMENTATIVE BACTERIA IN CIRRHOTIC PATIENTS; SMALL INTESTINAL BACTERIAL OVERGROWTH IN A IRRITABLE BOWEL SYNDROME CHILDREN POPULATION: A CASE-CONTROL STUDY; travel Grant winner.

28. National Meeting of the Italian Society of Internal Medicine: SIMI 2008, GENOVA, OCTOBER 25-28. 109° CONGRESSO NAZIONALE DELLA SOCIETÀ ITALIANA DI MEDICINA INTERNA. Oral communication: ⁵¹Cr-EDTA PERMEABILITY TEST IN ASCITIC CIRRHOTIC PATIENTS WITH AND WITHOUT HISTORY OF SPONTANEOUS BACTERIAL PERITONITIS. Prize winner “giovane ricercatore”.
29. Meeting (Italian) of the “SCUOLA SUPERIORE INTERDISCIPLINARE DELLE CEFALIE”: Florence, 24-26 October 2008. Lecture: “Cefalee Gastrointestinali”.
30. NGM (Neurogastro and motility International Joint Meeting) 2008: 6-9 November 2008, Lucerne. Posters: HUNGER PEAKS DURING FASTING AND POSTPRANDIALLY: RELATION TO UPPER GASTROINTESTINAL MOTILITY; INTERDIGESTIVE MOTILITY AND THE CONTROL OF HUNGER IN MAN;
31. XXI Belgian Week of Gastroenterology, Anverse 12-14 February 2009, Hilton Hotel. Oral communication: ROLE OF UPPER GASTROINTESTINAL MOTILITY STIMULATION IN THE OCCURRENCE OF HUNGER PEAKS; Poster: THE ROLE OF BODY MASS INDEX AND WAIST CIRCUMFERENCE ON REFLUX PATTERN AND EXTENT IN MAN;
32. Meeting of the Italian Association for the study of the liver: AISF 2009; 19-02-2009; Annual Meeting of the Italian Association for Liver Study, Aula Magna Università La Sapienza, Roma. Oral communication: ⁵¹Cr-EDTA PERMEABILITY TEST IN ASCITIC CIRRHOTIC PATIENTS WITH AND WITHOUT SPONTANEOUS BACTERIAL PERITONITIS;

33. **DDW 2009, 29 May - 3 June, Chicago, IL, USA. 3 Oral communications:**
INFLUENCE OF BACLOFEN ON THE POSTPRANDIAL ACID POCKET AT THE GASTRO-ESOPHAGEAL JUNCTION; INFLUENCE OF ITOPRIDE ON ESOPHAGEAL FUNCTION IN MAN; INFLUENCE OF THE CANNABINOID TYPE 1 RECEPTOR ANTAGONIST RIMONABANT ON ESOPHAGEAL FUNCTION IN MAN. 7 POSTERS: THE ROLE OF BODY MASS INDEX AND WAIST CIRCUMFERENCE ON REFLUX PATTERN AND PROXIMAL EXTENT IN MAN; RELATIONSHIP BETWEEN MIGRATING MOTOR COMPLEX AND PLASMA LEVELS OF GASTROINTESTINAL HORMONES IN MAN ; SPECIFIC UPPER GASTROINTESTINAL MOTILITY STIMULATION AND HUNGER PEAKS; RETURN OF HUNGER AFTER A MEAL: RELATION TO GASTRIC EMPTYING AND GASTROINTESTINAL MOTR PATTERNS; RIMONABANT-INDUCED EARLY SATIETY IS ASSOCIATED WITH DECREASED GASTRIC COMPLIANCE AND INHIBITION OF GASTRIC ACCOMMODATION; ⁵¹Cr-EDTA PERMEABILITY TEST IN ASCITIC CIRRHOTIC PATIENTS WITH AND WITHOUT HISTORY OF SPONTANEOUS BACTERIAL PERITONITIS; SMALL INTESTINAL BACTERIAL OVERGROWTH IN A IRRITABLE BOWEL SYNDROME CHILDREN POPULATION: A CASE-CONTROL STUDY;
34. **NGM joint International Meeting, 27-30 September 2009 Chicago, IL, USA:**
POSTERS: CORRELATION OF MOTILIN, OBESTATIN AND GHRELIN PLASMA LEVELS WITH HUNGER RATINGS AND MOTOR ACTIVITY IN MAN; SPECIFIC UPPER GASTROINTESTINAL MOTILITY STIMULATION AND HUNGER PEAKS; ROLE OF ENDOCANNABINOIDS IN THE CONTROL OF GASTRIC SENSORIMOTOR FUNCTION; IMPACT OF BODY MASS INDEX AND WAIST CIRCUMFERENCE ON REFLUX PATTERN AND PROXIMAL EXTENT IN MAN;
35. **5th Probiotic and Prebiotic International joint Meeting: Università Urbaniana, Roma 14-15 September 2009: Oral communication: Effect of Rifaximin on small bacterial overgrowth in childhood;**

36. **DDW2010, New Orleans: Oral communication: RELATIONSHIP BETWEEN SMALL INTESTINAL BACTERIAL OVERGROWTH AND INTESTINAL PERMEABILITY IN CIRRHOSIS; poster: EFFICACY OF RIFAXIMIN FOR SIBO TREATMENT IN A IBS CHILDREN POPULATION;**
37. **18th UEGW 2010, 23-27 October, Barcelona: 4 Poster, 2 best poster nominee: INFLUENCE OF COLONIC BACTERIAL FERMENTATION ON ABDOMINAL BLOATING IN IBS PATIENTS; ACCURACY OF CO₂ CORRECTED H₂ AND CH₄ VALUES IN BREATH TESTS; RELATIONSHIP BETWEEN SMALL INTESTINAL BACTERIAL OVERGROWTH AND INTESTINAL PERMEABILITY IN CIRRHOSIS; EFFICACY OF RIFAXIMIN FOR SIBO TREATMENT IN A IBS CHILDREN POPULATION;**
38. **Belgian week of Gastroenterology 2011, Liege, February 17 2011: poster INFLUENCE OF NALOXONE AND METHYLNALTREXONE ON INTERDIGESTIVE GASTROINTESTINAL MOTILITY AND HUNGER SCORES IN MAN;**
39. **DDW 2011, CHICAGO, IL, 6-9 MAGGIO 2011: 2 POSTER: EFFICACY OF RIFAXIMIN FOR SIBO TREATMENT IN A IBS CHILDREN POPULATION; INFLUENCE OF NALOXONE AND METHYLNALTREXONE ON INTERDIGESTIVE GASTROINTESTINAL MOTILITY AND HUNGER SCORES IN MAN;**
40. **EAGE POSTGRADUATE COURSE ON GI TRACT AND IMMUNITY, PRAGUE (CZ) 6-8 APRIL 2011: SPEAKER ON “ FOOD ALLERGIES “.**
41. **EAGE POSTGRADUATE COURSE ON OBESITY AND METHABOLIC SYNDROME, OPATIA (CT) MAY 2011: SPEAKER ON “ OBESITY AND INFLAMMATION “.**
42. **PROBIOTICS, PREBIOTICS AND NEW FOODS, Roma, Universita` Urbaniana, 11/11/2011, SPEAKER ON: “ GUT MUCUS BARRIER: A LITERAURE UPDATE “ .**

- 43.UEGW 2011, STOCKHOLM, 22-26 Ottobre 2011: POSTERs: **EFFICACY OF RIFAXIMIN FOR SIBO TREATMENT IN A IBS CHILDREN POPULATION; INFLUENCE OF COLONIC BACTERIAL FERMENTATION ON ABDOMINAL BLOATING IN IBS PATIENTS;**
- 44.**SIGE 2012, Naples 28-31 March 2012: 3 POSTER: EFFECT OF METHYLNALTREXONE ON ESOPHAGEAL FUNCTION IN MAN; INTESTINAL PERMEABILITY AND NICKEL ALLERGY; EFFICACY OF RIFAXIMIN FOR SIBO TREATMENT IN A IBS CHILDREN POPULATION;**
- 45.**DDW 2012, SAN DIEGO, CA, USA 9-12 May 2012: 1 ORAL PRESENTATION: EFFECT OF METHYLNALTREXONE ON ESOPHAGEAL FUNCTION IN MAN; 2 POSTER: INTESTINAL PERMEABILITY AND NICKEL ALLERGY; THE INFLUENCE OF ACUTE COLONIC FERMENTATION INDUCED BY ARABINOXYLAN-OLIGOSACCHARIDE (AXOS) ADMINISTRATION ON GASTRIC SENSORIMOTOR FUNCTION AND NUTRIENT TOLERANCE IN MAN.**
- 46.**Research meeting (Italian): AGGIORNAMENTI IN PATOLOGIA DIGESTIVA: Meeting di Primavera: " Le anemie, le patologie digestive e l'endoscopia : Ostia lido 16 Giugno 2012; speaker on: Anemia e parassitosi intestinale "**
- 47.**NGM 2012, BOLOGNA, FIERA, 6-8 September 2012: Poster : THE EFFECT OF ACUTE AXOS FERMENTATION ON THE INTERDIGESTIVE MOTILITY OF THE UPPER GI TRACT IN MAN.**
- 48.**INTERNATIONAL COURSE ON ULTRASOUND IN GASTROENTEROLOGY AND HEPATOLOGY, Bologna, 10-12 Settembre 2012, Policlinico S. Orsola.**
- 49.**EAGE Postgraduate course, Roma 4-5 Dicembre 2012, " I breath tests nella pratica clinica gastroenterologica: stato dell'arte e prospettive future ". Speaker on: " Breath tests and Orocecal transit time (OCTT)".**
- 50.**DDW 2013, ORLANDO (FL, USA), 18-21 May 2013: Poster: EFFECT OF BACLOFEN ON ACID POCKET IN MAN. Oral presentation: THE TRIANGULAR RELATIONSHIP BETWEEN LEAKY-GUT, MICROBIOTA AND SPONTANEOUS**

BACTERIAL PERITONITIS IN LIVER CIRRHOTIC PATIENTS.

51. **National Meeting of the Italian Society of Internal Medicine: SIMI 2013, ROME, 26-28th October 2013: Poster: EFFECT OF HYCHOLESTEROLEMIC DIET ON THE IMMUNE RESPONSE IN HCV PATIENTS.**
52. **Meeting (Italian): “ Gli incontri della verita’: Il fegato la tua salute “ , 6-7 Marzo 2014, National Council of the Researches, Rome.**
53. **Scuola Medica Ospedaliera, Ospedale S. Spirito, Rome: Up-date on Gut Microbiota and H.Pylori infection. Lecture on “ Consequences of altered Intestinal Permeability “. 21 Novembre 2014.**
54. **Breath. International Meeting. Novartis annual meeting. Rome.**
55. **Corso base SINPE, San Benedetto del tronto, 15-16 Maggio 2016, Relatore su “ Indicazioni alla nutrizione Artificiale “.**
56. **Pain management, the science behind. Menarini symposium. Budapest, 13-15 Ottobre 2016.**
57. **Corso base SINPE, San Benedetto del tronto, 15-16 Maggio 2016, Relatore su “ Indicazioni alla nutrizione artificiale nel periodo perioperatorio “.**
58. **Meeting of the Italian Association for the study of the liver: AISF 2018, Sapienza University of Rome, Rome, Italy.**
59. **THERE'S 2018 TIME FOR HEPATOLOGY RELEVANT SUGGESTIONS. Bologna, March 9-10 2018. Alfa-sigma meeting.**
60. **FNM 2018, Amsterdam, RAI convention center, August 29th-September the 1st. Poster: DUMPING SYNDROME INTERNATIONAL CONSENSUS CONFERENCE.**
61. **SINV annual meeting (Italian Society of Neuro-vascular sonography), Matera, November 16-18th 2019. Poster presenter: “ OPHTALMIC ARTERY FLOW ASSESSMENT IN LIVER CIRRHOSIS PATIENTS; CAROTID ARTERY STIFFNESS ASSESSMENT IN LIVER CIRRHOSIS PATIENTS “.**
62. **SINPE Annual Meeting (Italian society of Enteral and Parenteral Nutrition), Catania, November 22-24th 2019. Poster presenter: “USEFULNESS OF ABDOMINAL ULTRASOUND VS. CHEST X-RAY IN NASOGASTRIC TUBE POSITIONING CHECK IN MALNOURISHED PATIENTS; USEFULNESS OF BIO-**

IMPEDANCE MEASUREMENT IN RHEUMATOLOGIC PATIENTS MONITORING
“ .

63. **AISF ANNUAL MEETING, ROME, SAPIENZA UNIVERSITY, ITALY, FEBRUARY 2020. Submitted abstracts:** “ OPHTALMIC ARTERY FLOW ASSESSMENT IN LIVER CIRRHOSIS PATIENTS; CAROTID ARTERY STIFFNESS ASSESSMENT IN LIVER CIRRHOSIS PATIENTS “ .
64. **PRIMO CONGRESSO DI MEDICINA INTERNA DELLA PROVINCIA DI ASCOLI PICENO, SAN BENEDETTO DEL TRONTO, APRILE 2019, LETTURA SU “ EPATOPATIE AUTOIMMUNI “.**
65. **SINUC NATIONAL CONGRESS, September 2019, ANCONA, ITALY: Poster presenter:** “USEFULNESS OF ABDOMINAL ULTRASOUND VS. CHEST X-RAY IN NASOGASTRIC TUBE POSITIONING CHECK IN MALNOURISHED PATIENTS; USEFULNESS OF BIO-IMPEDANCE MEASUREMENT IN RHEUMATOLOGIC PATIENTS MONITORING “ .
66. **UEGW, October 19-23 2019, Barcelona Spain:** Poster presenter: “ OPHTALMIC ARTERY FLOW ASSESSMENT IN LIVER CIRRHOSIS PATIENTS; CAROTID ARTERY STIFFNESS ASSESSMENT IN LIVER CIRRHOSIS PATIENTS “
67. **ESPEN INTERNATIONAL CONGRESS, 31st of August-September the 3rd 2019, KRAKOW, POLAND: Poster presenter:** ““USEFULNESS OF ABDOMINAL ULTRASOUND VS. CHEST X-RAY IN NASOGASTRIC TUBE POSITIONING CHECK IN MALNOURISHED PATIENTS; USEFULNESS OF BIO-IMPEDANCE MEASUREMENT IN RHEUMATOLOGIC PATIENTS MONITORING “ .
68. **CBP EXPERT MEETING.** Discussant. December the 16th2019, Ancona, Italy.
69. **SECONDO CONGRESSO DI MEDICINA INTERNA DELLA PROVINCIA DI ASCOLI PICENO, SAN BENEDETTO DEL TRONTO, OTTOBRE 2020, LETTURA SU “ UN CASO DI LEISHMANIOSI VISCERALE “.**
70. **SINPE 2020, Virtual Meeting, November 2020, Oral communication on:** “ ROLE OF IMPAIRED NUTRITIONAL STATUS IN SARS-COV 2 PATIENTS “; **poster presenter:** “ USEFULNESS OF INDIRECT CALORIMETRY IN BODY-BUILDER AND NON-BODY-BUILDER ATHLETES FOLLOW-UP “.
71. **“LA MULTIDISCIPLINARIETA’ DEL CARCINOMA EPATOCELLULARE” (Italian), Marche regional virtual Meeting, March 2021, discussant.**
72. **ESPEN 2020, Virtual congress, Settembre 2020, poster presenter on:** “ ROLE OF IMPAIRED NUTRITIONAL STATUS IN SARS-COV 2 PATIENTS; USEFULNESS OF INDIRECT CALORIMETRY IN BODY-BUILDER AND NON-BODY-BUILDER ATHLETES FOLLOW-UP “ .

73. **ESPEN 2021, Virtual Meeting, Settembre 2021: poster presenter on:** “ ROLE OF IMPAIRED NUTRITIONAL STATUS IN SARS-COV 2 PATIENTS: A TWO-WAVE FOLLOW-UP STUDY; IMPACT OF COVID-19 PANDEMIC ON EATING HABIT AND MENTAL BEHAVIOR IN NON-PROFESSIONAL RUNNER VS. HEALTHY VOLUNTEERS “.
74. **“LA MULTIDISCIPLINARIETA’ DEL CARCINOMA EPATOCELLULARE” (Italian), Marche regional annual Meeting, Marzo 2022,** discussant.
75. **Nutrition in critical patient, SINPE special Meeting,** Spoleto, 10-11 Giugno 2022; lecture on: Oral food supplements in ICU recovery.
76. **DDW 2022, Maggio, SAN DIEGO, CA, USA,** Poster presenter: “ MANAGEMENT OF REFRACTORY GERD SYMPTOMS IN EUROPE EXPERT OPINION IN A CASE-BASED DELPHI APPROACH “.
77. **ESPEN 2022: Poster presenter on:** “ ROLE OF IMMUNE-NUTRITION IN SARS-COV 2 PATIENTS ADMITTED TO SEMI-INTENSIVE UNIT “; ROLE OF IMMUNE-NUTRITION IN SARS-COV 2 PATIENTS FROM A MILD INTENSITY CLINIC “, Vienna, ESPEN annual congress, Settembre 2022.
78. **TIPS REGIONAL MEETING, ANCONA, SETTEMBRE 2022,** Discussant.
79. **TERZO CONGRESSO DI MEDICINA INTERNA DELLA PROVINCIA DI ASCOLI PICENO, SAN BENEDETTO DEL TRONTO, NOVEMBRE 2022,** LETTURA SU “ NASH E NAFLD: UNA NUOVA SFIDE PER L’INTERNISTA“.
80. **SINPE 2022, Annual Meeting, November 2022, Poster presenter:** “ ROLE OF IMPAIRED NUTRITIONAL STATUS IN SARS-COV 2 PATIENTS “; “ ROLE OF IMMUNE-NUTRITION IN SARS-COV 2 PATIENTS ADMITTED TO SEMI-INTENSIVE UNIT “.
81. **FISMAD-SIGE ANNUAL MEETING, Rome, MARCH 2022, poster presenter:** “ EFFECT OF WHEY PROTEINS ON MALNUTRITION AND EXTUBATING TIME OF CRITICALLY ILL COVID-19 PATIENTS”;
82. **Nutrition in critical patient, SINPE special Meeting, Perugia, 9-10 Giugno 2023;** lecture on: Refeeding syndrome.

